US · Healthcare · Biotechnology
EPS came in at -1.14 against a street estimate of -1.10 — a miss of 3.6%.
Analysts rate Apogee Therapeutics, Inc. Common Stock a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $134.62.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 13.62% |
| FMR Inc | 12.25% |
| VR Adviser, LLC | 11.23% |
| BlackRock Inc | 5.40% |
| RTW INVESTMENTS, LLC | 3.68% |
| Vanguard Capital Management, LLC | 3.31% |
| HHG PLC | 3.12% |
| State Street Corp | 2.86% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 APOGEE THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Consideration: $135.11 per share in cash paid to shareholders • Total Equity | 2026-09-03 |
| Board / officer change · Q3 2026 APOGEE THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Apogee Therapeutics, Inc. (ticker: APGE, Nasdaq) • Record date shares outst | 2026-08-11 |
| Quarterly report · Q2 2026 APOGEE THERAPEUTICS, INC. – 10-Q SUMMARY HEADLINE NUMBERS • Cash and liquid assets as of June 30, 2026: $1.293 billion (cash $105.6M + short-term ma | 2026-08-10 |
| Results announced · Q3 2026 APOGEE THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Acquisition Price: AbbVie acquiring Apogee for $135.11 per share in cash • Total Eq | 2026-08-10 |
| Material agreement · Q2 2026 APOGEE THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Price: $135.11 per share in cash • Acquirer: AbbVie Inc. (via wholly owned su | 2026-06-22 |
| Quarterly report · Q1 2026 APOGEE THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash position: $451.8 million in cash and cash equivalents as of March 31, | 2026-05-11 |
| Proxy statement · Q2 2026 APOGEE THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III director nominees (Mark | 2026-04-24 |
| Annual report FY2025 APOGEE THERAPEUTICS, INC. – 10-K SUMMARY HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $1,757.9 million • Outstanding shares (as o | 2026-03-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| Merger with AbbVie consummated; company becomes wholly-owned subsidiary | 2026-09-03 |
| Stockholders approve merger with AbbVie in special meeting vote | 2026-08-11 |
| AbbVie to acquire company for $10.9 billion in cash transaction | 2026-08-10 |
| Entered into antibody discovery agreement with Paragon Therapeutics Apogee Therapeutics entered into two agreements with Paragon Therapeutics on June 17, 2026 to develop antibody treatments targeting IL-31R (interleukin 31 receptor), a protein involved in in | 2026-06-22 |
| Merger agreement with AbbVie announced; voting agreement with stockholders executed AbbVie Inc. is acquiring Apogee Therapeutics, Inc. in a merger transaction announced on June 22, 2026. The deal was signed on June 18, 2026, with a Merger Agreement between AbbVie (parent co | 2026-06-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Apogee Therapeutics, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.